The global FISH imaging systems market is expected to reach USD 1.4 billion by 2025, according to a new report. Increasing R&D investments pertaining to in vitro diagnostics are expected to drive the Fluorescence In Situ Hybridization (FISH) imaging systems market. Presence of government organizations, such as the European Diagnostic Manufacturers Association that focuses on development and growth of the in vitro diagnostics market in Europe, is also contributing to growth.
Furthermore, FISH imaging systems are gaining popularity in diagnostics for determination of suspected diseases caused by pathogens or bacteria. Increasing incidence of genetic diseases, such as lymphoma, solid tumors, leukemia, autism, and other developmental syndromes, is also expected to boost adoption. Growing penetration of fluoroscopy, microscopes, illuminators, and CCD cameras in testing for infectious diseases is expanding growth opportunities for these systems. Increasing prevalence of diseases with chromosomal aberrations, such as cancer and genetic abnormalities, as well as unmet diagnostic & clinical needs in developing countries, is anticipated to drive the market.
Moreover, increasing demand for rapid, sensitive, & accurate diagnostic techniques for validation of diseases, coupled with rising awareness, increase in healthcare expenditure, and extensive R&D for development of novel imaging systems are also expected to drive growth over the forecast period.
Further Key Findings From the Report Suggest:
Instruments held the largest market, whereas FISH imaging services are expected to grow at the fastest rate during the forecast period
At present, the market penetration of FISH imaging in cancer diagnostics is very high, hence the diagnostic laboratories segment accounted for larger revenues
Cancer diagnosis held the largest revenue share owing to increasing incidence of cancer, thus fueling adoption of FISH imaging systems
Among end-use segments, companion diagnostics is expected to witness faster growth than research and diagnostic segments
Diagnostic laboratories held the dominant position in 2016 as these systems are predominantly used in various clinical studies for visualization of precancerous lesions in cervical cancer, assessing risk of human papillomavirus, and for detection of leukemia, myelodysplastic syndrome, multiple myeloma, & chromosomal abnormalities
Companies Mentioned
BIOVIEW
West Medica Produktions- und Handels- GmbH
PerkinElmer, Inc.
Leica Biosystems Nussloch GmbH
Bio-Rad Laboratories, Inc.
BioTek Instruments, Inc.
GE Healthcare
Thermo Fisher Scientific, Inc.
TissueGnostics GmbH
Applied Spectral Imaging
MetaSystems
MR Solutions
Key Topics Covered:
Chapter 1 Research Methodology
Chapter 2 Executive Summary
Chapter 3 FISH Imaging Systems Market Variables, Trends & Scope
Chapter 4 FISH Imaging Systems Market: Product Estimates & Trend Analysis
Chapter 5 FISH Imaging Systems Market: Application Estimates & Trend Analysis
Chapter 6 FISH Imaging Systems Market: End-use Estimates & Trend Analysis
Chapter 7 FISH Imaging Systems Market: Regional Estimates & Trend Analysis, by Product, Application, End-use
FullCare Medical has launched a new medical garment production facility in Tatu City, the 5,000-acre mixed-use Special Economic Zone (SEZ) in Kenya....
Moleculin Biotech, Inc., (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced Walter Klemp, President and Chief Executive Officer of...
Neurent Medical, a company pioneering innovative non-surgical interventions to treat chronic inflammatory sinonasal diseases, today announced the appointment of Mr. John Peterson as the new Vice President of Sales & Marketing, effective immediately....
Endoscopy Equipment Market in terms of revenue was estimated to be worth $32.3 billion in 2024 and is poised to reach $46.2 billion by 2029, growing at a CAGR of 7.4% from 2024 to 2029 according to a new report by MarketsandMarketstm. The growth in...
Integrity Marketing Group, LLC ("Integrity"), one of the leading independent distributors of life, health and wealth products, today announced that Integrity Co-Founder and CEO Bryan W. Adams has been recognized as a top CEO for large companies in...
On March 28, 2024, Broncus Medical (02216.HK) (the "Company" or "we" ) announced annual results for FY 2023.
In 2023, Broncus Medical earned product sales of US$12.41 million, an increase of 32% compared to the previous year. Of which, total revenue...